IRIDEX Corporation Reports 8.2% Revenue Growth to $52.7 Million, Net Loss Improves

IRIDEX Corporation, a medical technology company specializing in ophthalmic laser systems, reported total revenues of $52.7 million for the fiscal year ending January 3, 2026, marking an increase of 8.2% from $48.7 million in the previous fiscal year. The growth was primarily driven by higher sales in its retina systems and glaucoma probes, alongside an additional selling week in the fiscal year. Despite the revenue increase, the company recorded a net loss of $4.4 million, an improvement from the $8.9 million loss reported in fiscal year 2024.

The company's gross profit decreased slightly to $19.2 million, resulting in a gross margin of 36.5%, down from 40.1% in the prior year. This decline in gross margin was attributed to inventory write-downs, increased product costs due to tariffs, and lower capitalization of manufacturing overhead as inventory levels fell. Operating expenses also decreased significantly, with research and development costs dropping by 32.7% to $3.7 million, and sales and marketing expenses down 17.4% to $10.4 million, reflecting cost-saving measures implemented by the company.

IRIDEX continues to focus on its proprietary MicroPulse® and Endpoint Management™ technologies, which are designed to treat glaucoma and retinal diseases with a safer profile compared to traditional high-energy laser treatments. The company has also expanded its market presence, with international sales accounting for 55.9% of total revenues in fiscal year 2025. The company’s strategic partnership with Topcon Corporation remains significant, as Topcon accounted for approximately 32% of total revenues during the fiscal year.

Looking ahead, IRIDEX faces challenges from macroeconomic conditions that may affect capital equipment purchasing decisions, including inflation and geopolitical uncertainties. The company has acknowledged that these factors could extend purchase decision cycles among customers. However, management remains optimistic about the market potential for its products, particularly in light of recent changes in reimbursement policies that may favor its advanced laser treatments for glaucoma.

As of January 3, 2026, IRIDEX had cash and cash equivalents of $6.0 million, an increase from $2.4 million at the end of the previous fiscal year. The company has also entered into financing agreements, including a $4 million convertible promissory note and the issuance of 600,000 shares of Series B preferred stock, which are expected to support its operational needs in the near term. The company anticipates that its existing cash and cash equivalents will be sufficient to meet its anticipated cash needs over the next 12 months, although it may require additional financing to support future growth initiatives.